Damage to the Nervous Tissue of the CNS with Intractable Spasticity & Medical Marijuana: PA & WV Qualifying Condition Guide

Damage to the nervous tissue of the central nervous system (CNS) the brain or spinal cord, can result in a range of neurological injuries, including intractable spasticity that does not respond adequately to standard treatment. Pennsylvania and West Virginia both recognize this condition as qualifying for medical marijuana. If you or a loved one is living with spasticity following a CNS injury, Compassionate Certification Centers can help you understand your options and determine whether certification may be appropriate as part of your care.

“Intractable” is an important clinical term: it specifically describes spasticity that has not responded adequately to standard first-line treatments such as oral antispasmodic medications, physical therapy, or botulinum toxin injections. This qualifying condition is intended for patients who have already tried conventional spasticity management without sufficient relief, not as a first-line alternative to standard care.

BOOK NOW

Diagnosis begins with identifying the underlying CNS injury through neurological examination and imaging (MRI or CT), followed by a clinical assessment of spasticity severity. Standardized clinical tools are used to evaluate spasticity, including:

• Modified Ashworth Scale (MAS): The most widely used clinical scale, grading muscle tone resistance from 0 (no increase in tone) to 4 (rigid).
• Spasm Frequency Scale: Measures how often involuntary muscle spasms occur.
• Numeric Rating Scale (NRS): Patient-reported severity of spasticity-related discomfort.
• Functional assessments: Evaluate how spasticity affects mobility, transfers, hygiene, and activities of daily living.

“Intractable” status is typically established after a patient has tried and not achieved adequate control with standard first-line treatments, which may include oral medications (baclofen, tizanidine, diazepam), botulinum toxin injections, physical therapy, or in some cases intrathecal baclofen pumps.

BOOK NOW

Cannabis-based treatment for spasticity is one of the more clinically developed areas of cannabinoid medicine but the strength of the evidence varies considerably depending on the underlying cause of the spasticity. The most robust data comes from multiple sclerosis research; evidence specific to traumatic brain injury, spinal cord injury, and stroke-related spasticity is comparatively thinner. This section presents that evidence honestly, including a significant recent setback in U.S. clinical trials. It is informational only and does not constitute medical advice.

1. Nabiximols (Sativex): The Most Studied Cannabis-Based Spasticity Treatment

Nabiximols, an oromucosal (under-the-tongue/cheek) spray containing a roughly 1:1 ratio of THC and CBD, is the most clinically studied cannabis-based medicine for spasticity. It has been approved since 2010 in the United Kingdom and is now licensed in more than 25 countries — including Canada, the UK, and most of Europe — specifically for moderate-to-severe MS-related spasticity that has not responded adequately to other anti-spasticity medications. Multiple European Phase 3 trials supported these approvals, generally showing modest but clinically meaningful reductions in patient-reported spasticity.

Importantly, nabiximols is not currently approved for any indication in the United States. A U.S.-specific Phase 3 trial (RELEASE MSS1) was conducted to support a potential FDA application; in 2022, the manufacturer announced that this trial did not meet its primary endpoint of reduced lower-limb muscle tone. This is a significant and recent finding that should be disclosed transparently: the strongest single cannabis-based spasticity product, despite approval abroad, has not yet demonstrated success in U.S.-based trial conditions. Further trials are ongoing.

2. Evidence Specific to Multiple Sclerosis Spasticity

Most of the available clinical trial evidence for cannabis and spasticity comes from MS patients rather than traumatic CNS injury patients. A 2025 systematic review and meta-analysis found that cannabis-based therapies were associated with clinically meaningful improvements in MS-related spasticity scores, particularly with longer treatment duration, though the authors cautioned that substantial heterogeneity between studies and possible publication bias warrant caution in interpreting the size of the effect. An earlier systematic review of whole-plant cannabis extracts found a therapeutic benefit trend on patient-reported spasticity, but no significant improvement on objective, clinician-measured spasticity scores — underscoring a recurring theme in this research area: patients often report feeling better even when objective measurements show more limited change.

3. Evidence Specific to Spinal Cord Injury & Traumatic Brain Injury

Evidence specific to spasticity caused by spinal cord injury (SCI) or traumatic brain injury (TBI) — as opposed to MS — is considerably more limited. A systematic review of cannabinoid use in spinal cord injury patients identified only 8 studies that directly investigated therapeutic effects on outcomes like spasticity, out of 34 total studies reviewed. The review concluded that current evidence suggests cannabinoids may reduce pain and spasticity in SCI patients, but that the effect magnitude and clinical significance remain unclear, and called for more rigorous controlled research specific to this population. Research specific to TBI-related spasticity is even more limited, consisting largely of small studies and case reports rather than controlled trials.

4. Mechanism: Why Cannabinoids Are Studied for Spasticity

The biological rationale for cannabinoids in spasticity stems from the role of the endocannabinoid system in regulating motor pathways and muscle tone in the central nervous system. Animal models of CNS injury have demonstrated that cannabinoid signaling can modulate spasticity-related neural circuits, providing a plausible mechanism that has guided decades of clinical research. As with other conditions, mechanistic plausibility does not by itself establish clinical effectiveness in humans — it is the rationale for research, not proof of an outcome.

5. Practical Considerations for Intractable Cases

Because this qualifying condition specifically applies to spasticity that has not responded to standard treatment, patients considering medical cannabis are typically already working with a neurologist or physiatrist managing complex, treatment-resistant symptoms. Cannabis-based approaches are generally considered as an adjunct to — not a replacement for — existing spasticity management, which may include oral medications, botulinum toxin injections, physical therapy, or intrathecal baclofen therapy. Coordination between a certified medical marijuana physician and the patient’s treating neurologist is especially important in these complex cases.

BOOK NOW

Both Pennsylvania and West Virginia recognize damage to the nervous tissue of the CNS with intractable spasticity as a qualifying condition. The certification process with Compassionate Certification Centers is straightforward:

Step 1: Register over the phone or online, next-day appointments are often available.

Step 2: Meet with a certified medical marijuana physician who will review your CNS injury history, current spasticity treatment, and documentation of treatment resistance to determine whether certification is appropriate.

Step 3: Receive your medical marijuana card and begin purchasing from licensed dispensaries in Pennsylvania or West Virginia.

Our physicians are experienced in working alongside neurologists, physiatrists, and rehabilitation teams and can help ensure that any cannabis-based approach is considered within the full context of your existing spasticity management plan.